Zeynep Eroglu

19PUBLICATIONS
115CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|Jan 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Andrew S Brohl, Vernon K Sondak, Evan J Wuthrick

|Jun 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.

Diwakar Davar, Zeynep Eroglu, Casilda Llácer Pérez

|Jun 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.

Diwakar Davar, Zeynep Eroglu, Mohammed Milhem

|Mar 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

Li Zhou, Milton Jose Barros E Silva, Edward Hsiao

|Mar 06, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Sarah A Weiss, Dijana Djureinovic, Wei Wei

Pageof 4

Frequent Collaborators

10 joint publications

Nikhil I Khushalani

5 joint publications

Vernon K Sondak

4 joint publications

Joseph Markowitz

4 joint publications

Ahmad A Tarhini